Ischemic Stroke in the Young

Samuel A. Berkman, MD¹ and Shlee S. Song, MD²

Abstract
The purpose of this article is to address several challenging questions in the management of young patients (those age 60 and under) who present with ischemic stroke. Do genetic thrombophilic states, strongly associated with venous thrombosis, independently cause arterial events in adults? Should cases of patent foramen ovale be closed with mechanical devices in patients with cryptogenic stroke? What are the optimal treatments for cerebral vein thrombosis, carotid artery dissection, and antiphospholipid syndrome and are DOACs acceptable treatment for these indications? What is the mechanism underlying large vessel stroke in patients with COVID-19? This is a narrative review. We searched PubMed and Embase and American College of physicians Journal club database for English language articles since 2000 looking mainly at randomized clinical trials, Meta analyses, Cochran reviews as well as some research articles viewed to be cutting edge regarding anticoagulation and cerebrovascular disease. Searches were done entering cerebral vein thrombosis, carotid dissection, anticoagulation therapy and stroke, antiphospholipid antibody and stroke, stroke in young adults, cryptogenic stroke and anticoagulation, patent foramen ovale and cryptogenic stroke, COVID-19 and stroke.

Keywords
stroke, young, thrombosis, cerebral, anticoagulation, closure

Date received: 09 February 2021; revised: 09 February 2021; accepted: 22 February 2021.

Cerebral Vein Thrombosis
Cerebral vein thrombosis (CVT) is associated with an identifiable hypercoagulable state in 85% of cases. These are most frequently hormone related conditions such as pregnancy, birth control pills and estrogens.¹ Other causes include paroxysmal nocturnal hemoglobinuria, myeloproliferative disorders, antiphospholipid antibody, and hereditary thrombophilia such as factor V Leiden or prothrombin 20210A mutations.¹ The patient frequently presents with headaches, which can be mistaken for a migraine with aura. It generally is slow in onset, building over several days, however, it also can present as a severe, ice-pick headache mimicking an acute migraine.²³

Papilledema is a frequent finding in thrombosis involving the superior sagittal sinus and should be sought after. Because a thrombosis can involve the inferior, sagittal, sigmoid, or straight sinus, funduscopic examination can be negative. Head CT is abnormal in only 30% of cases.⁴ The diagnosis is frequently made by MRI, but the best screening tests, depending on the institution, would be either a CT angiogram. CT Venogram, MRI, MRA and MR Venogram.

Predictive factors of poor prognosis includes CNS infection, thrombosis of the deep veins, intracranial hemorrhage, any malignancy, abnormal mental status, age greater than 37 and male gender.¹ There is a good outcome in 80% patients on heparin or low molecular weight heparin (LMWH).¹ CVT may present with intracranial bleeding due to back pressure from the thrombosis and presentation may be with a brain hemorrhage, counterintuitively requiring heparin.⁵

Two studies comparing heparin or low molecular weight heparin versus placebo have shown a trend favoring heparin, but did not reach statistical significance.⁶,⁷ Both studies lacked precision due to small sample size. A Cochrane review with meta-analysis of the same 2 trials involved only 79 patients and revealed a relative risk of .33 and relative risk of death or dependency of 0.46 in heparin treated patients versus untreated.⁸ There was no increase in symptomatic cerebral hemorrhages with the anticoagulants.⁸

¹ Division of Hematology-Oncology, Cedars-Sinai Medical Center, Los Angeles, CA, USA
² Department of Neurology, Comprehensive Stroke Center Program, Cedars-Sinai Medical Center, Los Angeles, CA, USA

Corresponding Author:
Samuel A. Berkman, Division of Hematology/Oncology UCLA, 9001 Wilshire Blvd, Suite 200, Beverly Hills, CA 90210, USA.
Email: sberkman@ucla.edu

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
Based upon these studies, international organizations such as the American College of Chest physicians and the American Heart Association/American Stroke Association have recommended either unfractionated or low molecular weight heparin as initial treatment for cerebral vein thrombosis.\textsuperscript{5,10} LMWH seems to be more effective and equally safe as heparin based on 2 comparative studies.\textsuperscript{11,12}

There is insufficient evidence that endovascular thrombolysis may be performed as a therapeutic option, however in patients with a poor prognosis and/or poor response to anticoagulation, it is not unreasonable to try.\textsuperscript{7} With respect to duration of therapy, European guidelines recommend 3 months of oral anticoagulation for patients with CVT provoked by a transient risk factor and 6 to 12 months for patients with idiopathic CVT and those with “mild” thrombophilia. They recommend indefinite oral anticoagulation for patients with either recurrent CVT or 1 episode of CVT and “severe” thrombophilia.\textsuperscript{2}

With respect to direct oral anticoagulants (DOACs), the European stroke organization 2017 guidelines recommended against their use, because patients with this diagnosis weren’t included in the pivotal trials of deep venous thrombosis comparing DOACs and vitamin K antagonists.\textsuperscript{13} However it would not be unreasonable to use them since they were non-inferior to vitamin K antagonist in treatment of venous thromboembolism in all of the pivotal trials and were associated with a 50% reduction in cerebral hemorrhage.\textsuperscript{14,15}

The randomized RESPECT trial was performed with 60 patients with cerebral vein thrombosis randomized to each group in a parallel group, open label, multicenter clinical trial with blinded endpoint adjudication.\textsuperscript{16} One group received Dabigatran 150 mg twice a daily and the other adjusted dose warfarin with the INR maintained between 2 and 3. They were followed for 22-23 weeks. These were patients who had acute cerebral vein thrombosis and were stable after 5-15 days of treatment with parenteral heparin. Patients with CVT associated with central nervous system infection or major trauma were excluded, however, those with intracranial hemorrhage were allowed. No recurrent venous thromboembolism was noted in either group. There was 1 major bleed in the Dabigatran group and 2 with warfarin. Whether other DOACs would perform equally was not addressed in this trial. This would be a concern in someone with CVT and renal disease, who would not be a candidate for Dabigatran.

A second prospective observational trial involved consecutive patients with clinical features of cerebral vein thrombosis confirmed with either CT or magnetic resonance imaging.\textsuperscript{17} People with infection or trauma were excluded.

A total of 111 patients were included, 45 on DOACs and 66 on warfarin. The groups were comparable except the DOAC patients had a higher incidence of headaches, 93% versus 63% and were significantly more likely than those in the warfarin group to have intracerebral hemorrhage on initial imaging. Follow-up ranged from 6-13 months and all patients underwent neurological examination at 6 months. Clinical neurologic worsening was reported in only 1 patient, and that was in the warfarin group. 6 patients reported major bleeding, 2 in the DOAC arm and 4 in the warfarin arm. This trial seems to confirm the RESPECT finding that DOACs are safe in this situation, including Rivaroxaban, which was the main DOAC in this trial.

A Meta-analysis of 5 studies published in 2020 consisting of 1 randomized and 4 observational trials showed an excellent functional outcome in 81.8% of DOAC patients versus 76.1% with warfarin.\textsuperscript{18} There was a 56% decrease in major bleeding with the DOACs at 1.32 versus 3.45; however this was not statistically significant (CI 0.12 to 1.59).

Another trial of 20 patients receiving Rivaroxaban with no previous heparin reported an excellent outcome in 19 of 20 patients at 6 months.\textsuperscript{19} Two other relatively small trials also showed favorable results with DOACs\textsuperscript{20,21} (see Table 1).

A new phase 3 trial called Secret will compare Rivaroxaban 20 mg daily versus standard of care which would be either unfractionated heparin, low molecular weight heparin with transition to vitamin K antagonists or continuation with low molecular weight heparin.\textsuperscript{22} The primary outcome measure will be a composite rate of all-cause mortality, symptomatic intracranial bleeding, and major extracranial bleeding over 180 days. Secondary outcome measures will be all cause mortality, symptomatic intracranial bleeding, major extracranial bleeding, recurrent venous thromboembolism, and major bleeding or clinically relevant non major bleeding.

At this time it would seem that DOACs, particularly Dabigatran, and to a lesser degree Rivaroxaban would be reasonably safe alternatives to warfarin for preventing recurrent DVTs in patients with CVT after initial unfractionated heparin or preferably LMWH. While the American Heart Association and American Stroke Association recommended against DOACs, those statements were generated in 2013.\textsuperscript{23} The American Society of Hematology in their 2019 DVT treatment guidelines was silent in this area.

**Cervical Artery Dissection**

Cervical artery dissection (CD) is a rare cause of stroke, but among people under 45, it comprises 25% of cases.\textsuperscript{24} CD are more commonly seen in the upper cervical spine internal carotid or vertebral artery.\textsuperscript{25} It may seem risky and counterintuitive to administer anticoagulation for a torn blood vessel, but cerebrovascular dissections are rarely actual ruptures of the vessel; more often, they are separations of the intima from the rest of the vascular wall and the prothrombotic intimal flap is a source of distal emboli.\textsuperscript{26}

Dissections can occur from trauma associated with mechanical forces of rapid acceleration, deceleration, and torsional forces (e.g. motor vehicle accident, chiropractic neck manipulation, roller coasters), but most occur spontaneously and are labeled as “idiopathic.”\textsuperscript{27,28} The etiology of spontaneous dissections is unknown but structural anomalies (e.g. Eagle Syndrome) or underlying collagen vascular diseases have been associated with CD.\textsuperscript{29,30} In a large series of patients with cervical artery dissections, those with internal carotid artery
Table 1. DOACS in Cerebral Vein Thrombosis.

| Study | DOACS | Comparator | Results |
|-------|-------|------------|---------|
| Ferro JM, et al. JAMA/NEUROLOGY 2019 Reference 16 | LMWH/heparin then Dabigatran 60 patients | LMWH/heparin then VKA 60 patients | a.) No recurrent VTEs observed in either group  
b.) One (1.7%) major bleeding event dabigatran (95% CI, 0.0-8.9) and 2 (3.3%; warfarin (95% CI,0.4-11.5) |
| Wasay M, et al. Journal of Stroke 2019 Reference 17 | LMWH/heparin then Dabigatran or Rivaroxaban 45 patients | LMWH/heparin then VKA 66 patients | Pts underwent neurological exam at 6 months  
Clinical neurologic worsening reported only in 1 patient in warfarin group.  
6 patients with systemic bleeding (ISTH classification—1 Major, 1 Non-Major, and 4 Minor), 2 were on DOACs, 4 on warfarin |
| Shankar R, et al. Clinical Neurology and Neurosurgery 2018 Reference 19 | Rivaroxaban 20 mg a day 20 patients | No comparator group-single arm study Rivaroxaban with no previous heparin reported an excellent outcome in 19 of 20 patients at 6 months. Critically ill and surgical intervention patients were excluded |
| Herweh C, et al. European Journal of Neurology 2016 Reference 20 | LMWH/heparin and then DOAC 13 patients | LMWH/heparin-3 remained on LMWH, other 83 patients on VKA | 89 of 99 with excellent outcome (mRS 0-1); death 2 of 99. No severe hemorrhagic complications or recurrence of CVT on follow-up at median of 8 months. Complete recanalization in 57.6% at 6 months. Partial recanalization in 29.3% at 4 months |
| Mendonca M et al. International Journal of Stroke 2015 Reference 21 | LMWH/heparin then Dabigatran in 11 patients and 7 on Warfarin. 4 patients switched from Warfarin to Dabigatran. Total of 15 on Dabigatran | None | Median follow-up was 19 months. Excellent outcome in 87% and recanalization in 80% |
dissection (ICAD) were more common than vertebral artery dissections (VAD) and ICAD had less neck trauma to report than VAD patients. Patients with dissection related stroke have not been excluded from thrombolysis trials despite the theoretic risk of hematoma. Carotid dissection with flow limiting stenosis is occasionally considered for stenting, but this is a controversial point, as treatment is basically medical management with antithrombotic, either antiplatelet therapy or anticoagulation.

In a systematic review of 762 patients with cervical dissections, Menon et al did not find a significant difference in the risk of stroke with antiplatelet therapy (1.9%) versus anticoagulant therapy (2.0%). The risk of death was 1.8% with antiplatelet therapy and 1.8% with anticoagulants. A 2012 meta-analysis of nonrandomized studies with over 1600 patients with cervical artery dissection also reported no significant difference in recurrent stroke risk or mortality comparing anticoagulation with antiplatelet therapy.

A review of 38 studies, none of which were randomized, involving 1398 patients showed no differences in death, death and disability, ischemic stroke or symptomatic intracranial hemorrhage between recipients of antiplatelet and anticoagulant therapy. The authors felt that absent a randomized trial there was no good means of distinguishing between the options.

The CADISS trial was a randomized trial comparing antiplatelet versus anticoagulation therapy in patients with cervical artery dissection. It involved 250 patients; 118 with carotid dissection and 132 with vertebral dissection. 126 patients were assigned to antiplatelet treatment versus 124 to anticoagulation. In the entire trial 4/250 (2%) patients experienced a stroke recurrence. Stroke or death occurred in 3 of the 126 patients in the antiplatelet group (2%) versus 1 of 124 in the anticoagulant group (1%). The confidence interval was 0.006-4.233. There was no difference in the efficacy of antiplatelet and anticoagulant drugs in preventing stroke and death.

A second large trial, which was not randomized, looked at anticoagulation versus antiplatelet treatment in patients with carotid and vertebral artery dissection, but in contrast to CADISS, included patients with intracranial involvement. The mean follow-up in the study was 24 months. 55% of patients received antiplatelet therapy, with the choice of drug or combination at the discretion of the treating doctor. 29.4% of those in the trial received anticoagulation and 12.6% received combined treatment.

Ischemic or hemorrhagic events occurred in 9.6% of the patients on antiplatelet and 10.4% of those on anticoagulation, and 13.3% occurred on combined treatment. This study included both traumatic and spontaneous dissections. In intracranial versus cervical dissection, it was more likely the patient with intracranial dissection would be placed on antiplatelet therapy, however, the results were no different. Another trial prospectively collected data from 298 patients with spontaneous dissection of the cervical carotid artery and showed very low incidence of ischemic events during follow-up. There was no difference in ischemic or hemorrhagic events between those treated with anticoagulants and those with aspirin (see all trials in Table 2).

While the American College of chest physician’s 2012 guidelines recommended 3-6 months of anticoagulant therapy, many studies since then indicate no evidence for superiority of anticoagulation over antiplatelet agents. Given both antiplatelet and anticoagulation are acceptable treatment options for carotid dissection, stroke prevention, experts may weigh a patient’s comorbidity profile or history of compliance in choosing the patient’s antithrombotic treatment.

For those with recurrent ischemic events despite optimized medical management, endovascular treatment options like stenting may be considered. Imaging studies indicating flow discrepancy in the culprit CD artery territory may be helpful in consideration for endovascular treatment options. Flow limitation due to CD may cause perfusion dependent dysfunction that may be salvageable, e.g. penumbral tissue. In such cases, stenting may restore vessel caliber and intracranial perfusion given antithrombotic treatment alone may not restore normal cerebrovascular flow. Imaging studies such as Transcranial Doppler (TCD), CT perfusion (CTP), and MR perfusion (MRP) can demonstrate hypoperfusion associated with CD.

**Antiphospholipid Antibody Syndrome**

Antiphospholipid antibody syndrome (APS) involves an arterial or venous thrombotic event, or pregnancy losses in connection with positivity of an antiphospholipid antibody. There needs to be a confirmation of the tests 12 weeks later. The 3 relevant antibodies are lupus anticoagulant, anticardiolipin antibody, and anti-beta-2 glycoprotein. Anti-phosphatidyl serine has been correlated with thromboembolism in patients with APS but has not yet been accepted as an official criterion.

It has been suggested that more than 20% of strokes in patients under 45 are associated with APS. Although the mechanisms of cerebral involvement are not completely understood, multiple mechanisms are postulated. These include disruption of the Annexin shield, allowing antiphospholipid antibody to disrupt the endothelium, inhibition of the protein C pathway, activation of platelets as well as diffuse expression of adhesion molecules, and tissue factor in the endothelium. More recently, and the activation of complement has been discovered and found to be particularly relevant in catastrophic antiphospholipid antibody syndrome. A complement factor, platelet bound C4d, which sits at the intersection of the anticoagulation and complement pathways, also has value in predicting thrombosis risk among lupus patients.

Ischemic stroke is the most common and severe complication of arterial disease of antiphospholipid syndrome. The stroke mechanism in APS may be thrombotic or embolic. The clinical manifestations will depend on the location and size. It can involve not only small arteries but also larger arteries as well. Embolic stroke occurs mainly because of valvular lesions due to deposition of immune complex Libman-Sacks vegetations in association with systemic lupus erythematosus (SLE).
There are numerous other neurological signs of cerebrovascular disease in APS as it has been associated with cognitive dysfunction,53 migraine,54 seizures,55 multiple sclerosis type syndrome,56 neuro-ophthalmology involvement,57 psychiatric manifestations,58 as well as transverse myelitis,59 and movement disorders.60 Patients who are positive for lupus anticoagulant are more susceptible to thrombosis than those with anticardiolipin or anti-beta-2 glycoprotein.61 Also patients who are triple positive are more susceptible than double or single positive patients to an initial event as well as recurrent thrombosis.62

Heparin use in antiphospholipid syndrome has been restricted to the treatment of catastrophic antiphospholipid syndrome as well as 2 studies involved with the rescue of people who were felt to be resistant to warfarin.63 With respect to arterial disease, the recommended treatment is heparin transitioning to warfarin. More controversial is the dose of warfarin. 2 studies showed that maintaining the INR between 2 and 3 was superior to higher dosages with respect to both thrombosis and bleeding complications in both arterial and venous disease.46,64 However, the European league against rheumatism (EULAR) recommendations are for a target INR between 3 and 4 in APS patients with ischemic stroke in antiphospholipid syndrome.65 The American College of chest physician’s recommends the INR prolongation to be between 2 and 3.

There has only been one trial which has compared antiplatelet therapy with Warfarin. Based on the APASS trial involving 1770 individuals with stroke, it appears that both warfarin and aspirin appear to be reasonable antithrombotic treatment options for patient with a first-time arterial ischemic stroke with antiphospholipid syndrome.66 With respect to the use of direct oral anticoagulants in APS, a trial from England involving 120 patients with thrombotic antiphospholipid syndrome compared 6 months of Rivaroxaban; 20 mg a day versus dose adjusted warfarin with an INR

| Study | Ref | Strategy I | Strategy II | Results |
|-------|-----|------------|-------------|---------|
| Anitcoagulant Versus Antiplatelet Therapy in Cervical and Vertebral Artery Dissection. |
| Menon | 32 | Anticoagulant therapy n = 484 | Antiplatelet therapy n = 268 | No significant difference between groups a.) stroke 5/268 – 1.9% in antiplatelet group. 10/494 (2.0%) anticoagulant group CI – 6% to 4% b.) death—antiplatelet 5/268 (1.8%, anticoagulation; 9/494 1.8%) |
| Geogiadis | 31 | Anticoagulant therapy n = 202 | Antiplatelet therapy n = 96 | a.) 5.9% incidence of new ischemic events on anticoagulation, 2.1% on aspirin. b.) Hemorrhagic events 2% on anticoagulants, 1% on aspirin |
| Kennedy | 33 | Anticoagulant therapy n = 1137 | Antiplatelet therapy n = 499 | No significant difference between groups Recurrent stroke risk was 2.6% with platelets and 1.8% with anticoagulants. Risk of death was 1% with platelets and 0.80% with anticoagulant |
| Chowdhury | 34 | Anticoagulant therapy n = 1047 | Antiplatelet therapy n = 428 | No significant differences Primary outcomes All cause death CI from -0.095 to .081, P = .871 2. Death and disability CI -1.57 TO.146 P:940 Secondary outcome 1. Ischemic stroke Anticoagulants 1.74% vs 1.43 in antiplatelet 2. symptomatic intracranial hemorrhage only in AC group 5/697.72%, P = .364 |
| CADISS trial | 29 | Anticoagulant therapy n = 124 patients | Antiplatelet therapy n = 126 | No significant difference between groups. Stroke or death occurred in 3 (2%) of 126 patients on antiplatelets versus 1 (1%) of 124 patients on anticoagulants (OR 0.346, CI 0.006-4.390; P = 0.66) |
| Daou et al | 30 | Anticoagulant therapy n = 100 | Antiplatelet therapy n = 100 | No significant difference between groups. Recurrent ischemic or hemorrhagic events in 9.6% on antiplatelets 10.4% on anticoagulants. Pts with intracranial dissection 8.5% on antiplatelets, 15.4% on anticoagulant, and 18.2% on combined treatment |
between 2 and 3. While the trial was not considered successful because the primary endpoint was endogenous thrombin potential (ETP) which was higher in Rivaroxaban patients than those on warfarin, the study nonetheless showed no cases of thrombosis or bleeding in either group at 6 months. However, there were very few patients with triple positive antibodies, and people with arterial disease were excluded.67

The TRAPS study, focusing on triple positive patients, studied a population highly enriched for thrombotic risk. The dose of Rivaroxaban was 20 mg compared with Coumadin with an INR maintained between 2-3 after initial treatment with heparin. The trial was terminated prematurely after the enrollment of 120 patients because of an excessive number of events in the Rivaroxaban arm. There were 11 events (19%) in the Rivaroxaban arm and 2 (3%) with warfarin. Major bleeding 6 pts, 4 Rivaroxaban (7%) and 2 (3%) warfarin no deaths

A randomized clinical trial from Spain also compared Rivaroxaban 20 mg per day versus vitamin K antagonist therapy, maintaining the INR between 2 and 3, or between 3 and 4, for people with a previous history of multiple thromboses. Approximately 60% of those had triple positivity. Recurrent thrombosis occurred in 11.6% in the Rivaroxaban arm and 6.3% on the vitamin K antagonist arm. Specifically ischemic stroke occurred in 3.4% in the Rivaroxaban group and 0/61 in the warfarin group. The results of overall thrombotic events were driven by arterial thrombosis in favor of rivaroxaban 20 mg compared with Coumadin with an INR maintained between 2-3 after initial treatment with heparin. The trial was terminated prematurely after the enrollment of 120 pts—excessive events in Rivaroxaban arm.

Table 3. DOACs in Antiphospholipid Antibody Syndrome.

| Study          | Treatment group            | Comparator group       | Results                                                                 | Comments                                                                 |
|----------------|-----------------------------|------------------------|------------------------------------------------------------------------|--------------------------------------------------------------------------|
| RAPS 2016      | Rivaroxaban 20 mg a day     | Warfarin INR maintained | No thrombotic or bleeding events in either group                        | No arterial thrombosis patients in study. About 30% triple positive. The primary endpoint was thrombin generation in favor of warfarin |
| Ref 67         | for 6 months                | between 2-3            |                                                                         |                                                                          |
| TRAPS 2018     | Rivaroxaban 20 mg a day     | Warfarin INR between    | 11 events (19%) in Rivaroxaban arm and 2 (3%) with warfarin. Major bleeding 6 pts, 4 Rivaroxaban (7%) and 2 (3%) warfarin no deaths | Trial terminated prematurely after enrollment of 120 pts—excessive events in Rivaroxaban arm |
| Ref 68         | triple positive pts         | 2-3 triple positive pts |                                                                         |                                                                          |
| ORDI-ROS 2019  | Rivaroxaban 20 mg a day     | Warfarin INR between    | Recurrent thrombosis 11.6%                                              | Results were driven by arterial thrombosis                               |
| Ref 69         | 60% triple positive pts     | 2-3, 3-4 in pts with   | Rivaroxaban 6.3% vitamin K antagonist                                   |                                                                          |
|                |                             | previous history of     |                                                                         |                                                                          |
|                |                             | multiple thrombosis 60% |                                                                         |                                                                          |
|                |                             | triple positive pts     |                                                                         |                                                                          |
| Dufrost 2018   | DOACs meta-analysis 447 pts | None                   | 73/447 (16%) recurrent thrombosis on DOACs                              | Increased risk for triple positive                                       |
| Ref 70         |                             |                        |                                                                         | 56% vs 23%, arterial thrombosis                                          |
| RISAPS phase2/3| Rivaroxaban 15 mg twice a   | Warfarin target INR 3.5 | Collecting data                                                          | History of APS and stroke or other ischemic brain manifestations         |
| 2020 Ref 71    | day                         |                        |                                                                         |                                                                          |

Based upon these trials, the European Medicines Agency74 and the European Society of cardiology75 came out with recommendations against DOACs for antiphospholipid syndrome. In patients who have events on warfarin, other treatments such as rituximab, hydroxychloroquine, and statins have been discussed. Since Coumadin requires several days of transition with low molecular heparin and has many other inconveniences, there are ongoing trials to try to isolate a population of antiphospholipid antibody patients who might be candidates for DOACs. One of the new developments in APS is the increasingly recognizable phenomenon of complement activation in antiphospholipid antibody syndrome. Patients with catastrophic antiphospholipid antibody syndrome have a high incidence of this activity.76 Patients, who have not responded to the usual measures for catastrophic APS such as corticosteroids, plasma
exchange, intravenous immunoglobulin, and Rituxan, could be candidates for Eculuzimab, an inhibitor of C5. This drug has been very successful in the treatment of 2 other diseases characterized by excess complement activity, including paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.

It would seem at this time that triple positive patients and people with a history of arterial disease should unequivocally not receive DOACs. Whether a suitable population can be found where it would be acceptable to give DOACs will depend on future studies (summary of these trials in Table 3).

Closure of Patent Foramen Ovale to Prevent Paradoxical Embolus

Patent foramen ovale occurs in about 25% of adults. Some studies have shown young adults with strokes secondary to patent foramen ovale had a high incidence of accompanying prothrombotic states. 3 randomized trials performed a decade ago compared transcatheter surgical closure of these defects to medical therapy with antiplatelet agents or anticoagulants. People in the surgical intervention arm also received antiplatelet therapy. None of these trials showed a statistically significant advantage in intention to treat toward closure. However, they all demonstrated trends in favor of the intervention and the trials using the Amplatzer occluder device showed greater safety versus those using the Starflex.

Of the 3, the RESPECT trial came the closest to showing superiority in intention to treat with a hazard ratio of 0.5 and a P value of 0.08 for superiority with respect to closure versus medication. It actually did achieve superiority in on treatment analysis. However, the study’s precision was undermined by a wide confidence interval due to the small number of patients.

People with a large shunt and with a septal aneurysm did have a statistically significant advantage in that trial. The other 2 trials, the PC trial and the Closure 1 trial also showed a decreased hazard ratio with respect to measures such as recurrent stroke, TIA non-fatal stroke, but neither demonstrated statistical significance in intention to treat.

An editorial which accompanied the Respect and PC publications, while stating the pros and cons, opined that one should be circumspect about interpreting the low hazard ratios and decreased complication with the Amplatzer device as license to freely employ closure strategy.

More recently the needle has shifted in favor of these devices, based upon new randomized trials. Meta-analyses which include all of these trials have shown that the intervention is associated with a decreased risk for recurrent ischemic stroke compared with those on antiplatelet treatment. However, all of these trials have had limitations, including the exclusion of people over 60. They also do not show an improvement in TIA recurrence rate or mortality benefit and some of them have shown temporary increases in atrial fibrillation. Features such as large shunt size and presence of an aneurysm in the atrial septum have been factors more likely to be associated with success.

Also unsettled is the role of anticoagulant therapy. If a person has an ischemic stroke and patent foramen ovale with an accompanying deep venous thrombosis, are they better off with closure versus long-term anticoagulation therapy, whether stand alone or combined with closure procedures? Long-term anticoagulation therapy for this condition would be associated with a risk of major bleeding of 3% per year and 0.3% per year of cerebral hemorrhage.

It would appear at this time that these procedures are safe and indicated in numerous patients age 60 or under, with a cryptogenic stroke and patent foramen ovale, especially people with a large shunt with or without septal aneurysm. Reasons brought up to explain the difference between the 3 most recent trials and the initial 3 could be longer follow-up, better occlusive devices, and/or better selection of patients (summary of these trials is shown in Table 3).

Hereditary Thrombophilia

Are mutations for factor V Leiden, Prothrombin 20210A, or deficiencies in antithrombin, protein C, or protein S causative or incidental in the pathogenesis of cryptogenic stroke in patients without a patent foramen ovale?

The controversy is fueled by findings from small case reports and meta-analyses which have shown mild trends of these thrombophilic conditions causing stroke mainly in children, however it is questionable whether a single mutation would be sufficient to predispose a child to a stroke. It is also unclear why there would be a difference in this predisposition between children and adults.

Regarding adults, large prospective cohort studies like the Physician’s Health Study and the Cardiovascular Health Study have not shown such a relationship in patients with factor V Leiden or prothrombin 20200A mutations, and the standard of practice has been to treat patients having these abnormalities on a case by case basis, mainly using antiplatelet therapy. Case reports have suggested that protein S and C deficiencies may play a causative role in young patients and middle aged women with cryptogenic stroke. However, these findings have not been substantiated in case controlled or prospective studies, therefore protein S and C levels have not been routinely sought in stroke patients.

A large German meta-analysis showed a statistically significant increase in factor V Leiden mutation associated with patients with ischemic stroke versus those without the mutation but not with prothrombin 20210A mutations.

Another trial from Italy looked at 97 patients whose main age was 40.9 years with first ever cerebrovascular events. They were compared to age-matched control patients. Factor V Leiden and prothrombin 20210A mutations were detected with a 4.7 fold greater incidence in stroke patients than in the controls. These were all patients with patent foramen ovale who had been referred for percutaneous trans catheter closure. An additional retrospective review showed a 13% incidence of protein C, protein S, or antithrombin deficiency in adults less than 45 years with ischemic stroke. Only 3% had factor V Leiden and prothrombin 20210A mutations.
A retrospective review studied all patients with stroke and TIA ≤ 60 years presenting to University College London Hospital stroke unit and daily TIA clinic from 1 January 2015 to 1 August 2016 with the average age of the patients being 49.1 years. Thrombophilia testing was reported in 360 patients including 171 with stroke and 189 with TIA. 14% of patients had positive tests with antiphospholipid antibody being most common. Thrombophilia mutations and deficiencies of protein C and S, and AT, were very uncommon. Follow-up testing was done in less than 10% of patients.101

Another retrospective, observational, single center study involving 143 patients with stroke or TIA, reported that the most common positive tests were elevated factor VIII activity in 18% and protein S in 11%. Testing altered clinical management in

| Study          | Ref | Strategy I                              | Strategy II                           | Results                                                                 |
|----------------|-----|-----------------------------------------|---------------------------------------|-------------------------------------------------------------------------|
| CLOSURE I      | 80  | Starflex device closure then ASA + Plavix x6 months then ASA | ASA, Warfarin or both                  | Primary end point: Composite of stroke, TIA, at 2 yrs. + 30 day all-cause mortality—and neurologic mortality beyond 30 day-2 years: Lower rates of events with closure device but not statistically significant. HR 0.78 (CI 0.45-1.35) P = .37 No deaths in either group 30 days, no deaths neurologic causes 2 year follow up Cardiovascular complications greater with closure device particularly atrial fibrillation |
| PC             | 81  | Amplatzzer PFO occluder 325 mg po qd for 5-6 months | Medical treatment left to discretion of treating physician whether anticoagulation or antiplatelet therapy | Primary endpoint Death, non-fatal stroke, TIA or peripheral embolism less frequent in occluder treated patients but not statistically significant.7/204(3.4%) closure vs 11/210 5.2% medical therapy HR 0.63(CI .24-1.62) P Slightly more adverse events with occluder |
| RESPECT        | 82  | Amplatzzer PFO occluder                  | Medical therapy—1 or more antiplatelet medications (74.8%) or warfarin (25.2%) | Decrease events (fatal ischemic stroke, early death, recurrent ischemic stroke) with occluder—but not statistically significant. HR.49( intention to treat (CI 0.22 to 1.11) P value .08 Per protocol HR 0.37(CI-0.14-0.96) P = .03 Serious procedure related adverse events 4.2% |
| CLOSE          | 86  | Multiple devices                         | 32.8% aspirin 28% anticoagulation         | Randomized trial, 3 groups a.) 238 patients received closure plus APT, b.) APT or c.) oral AC 6% strokes (14/235) with medical therapy 0 with closure.—closure increased incidence of Afb |
| REDUCE         | 85  | Gore septal occluder                     | Antiplatelet therapy                     | 1.4% strokes with closure, 5.4% in medical group (CI 0.9-6.2) P=002 New brain infarcts 4.7% vs 10.7 % RR = .44 (CI 0.24-81) Device related events 1.4%. Afb 6.6% in device pts |
| Defense PFO    | 87  | Amplatzzer 100 mg/day in combination with clopidogrel 75 mg/day for at least 6 months after the Procedure. | Antiplatelet therapy included aspirin, aspirin in combination with clopidogrel at a dose of 75 mg/day, or aspirin in combination with Clofrostazol at a dose of 200 mg/day | 120 patients with cryptogenic stroke and high risk PFO underwent randomization. The primary endpoint was stroke, death or major bleeding 10.5% primary endpoint with medications 0 with closure |
| RESPECT 2      | 84  | Amplatzzer 81 to 325 mg aspirin and clopidogrel for 1 month then ASA for 5 months | a. Warfarin, or b ASA c. Clopidogrel or d. ASA plus dipyridamole | Recurrent ischemic stroke PFO vs medical therapy 18/499 = 0.58 events per 100 pt. years with Closure vs 28/481 = 1.07 events/ 100 pt. years with medical therapy HR 0.55 CI (.31-.999) P = 0.046 |
only 1% of the total patients tested. 33 patients (75%) had the potential for carrying a misdiagnosis due to positive tests that were only never verified. The collective annual cost of testing was approximately $62,000. The conclusion was that thrombophilia testing in the acute, inpatient setting of stroke or TIA rarely changed management. This remains a controversial area (see Table 5).

It appears that case reports are most likely to report this association between thrombophilia and cryptogenic stroke versus registry, and other larger observational trials which show that thrombophilia testing in the acute, inpatient setting of stroke or TIA, in patients without a PFO rarely changes clinical management of patients admitted with stroke or TIA.102

Another review of 165 patients hospitalized for Covid-19 multiorgan dysfunction, showed evidence of endothelial disruption and large artery mononuclear and neutrophil infiltration. The cascade of endothelial dysfunction may be vascular, endothelial injury and excessive platelet activation with resultant related thrombosis in cerebrovascular vessels.105

Thrombophilia testing rarely impacted management and was costly

Very low incidence of antithrombin protein C and protein S. If one decides to test it should be repeated to distinguish bona fide thrombophilia from false positives

Possibly numerous false positives—cutoffs for PC< 70%, PS <70% and AT < 80. Most common abnormal test—PS which is subject to acute phase effects

In cryptogenic stroke patients with PFO, 55 years or younger, prothrombotic factors such as FV Leiden and PT G20210A can help identify those with increased risk for ischemic stroke and adjust prevention treatment as needed

**COVID-19 Strokes in Young Patients**

It remains to be seen exactly what the mechanisms are behind large vessel strokes in young people with COVID-19. Mechanisms for the increased risk of acute stroke include an inflammatory cascade and hypercoagulable state with serum elevated C-reactive protein, D-dimer, and ferritin.103 According to Varga et al there was evidence of direct viral infection of endothelial cells and inflammation with the virus utilizing the ACE2 receptor.104 The ACE2 receptor is prominent in lung epithelium but is also expressed on endothelial cells across multiple organs. Specifically in the brain, the SARS-CoV2 virus binds to angiotensin converting enzyme 2 (ACE2) receptors present on brain endothelial cells. ACE2 is a key part of the renin–angiotensin system and is a counterbalance to angiotensin converting enzyme I (ACEI) which gives rise to angiotensin II, which is a pro-inflammatory vasoconstrictor, which can promote organ damage. With the depletion of ACE2 by SARS-COV2, the balance may be tipped in favor of the harmful ACEI / angiotensin II axis, with the promotion of brain injury, including both hemorrhagic and ischemic stroke.105

Post-mortem evaluation from patients who deteriorated from COVID-19 multiorgan dysfunction, showed evidence of endothelial disruption and large artery mononuclear and neutrophil infiltration. The cascade of endothelial dysfunction may be vascular, endothelial injury and excessive platelet activation with resultant related thrombosis in cerebrovascular vessels.105

A recent retrospective cohort study of 1916 patients from New York City hospitals showed that approximately 1.6% of adults with COVID-19 who visited the emergency room or were hospitalized, experienced an ischemic stroke.106 This was a higher rate compared with a cohort of patients with influenza. Another review of 165 patients hospitalized for Covid 9 showed that the main risk factor for stroke was severity of disease. This was confirmed in a systemic systematic review and meta-analysis involving 576 patients which showed that aside from a tendency toward a higher proportion of past history of cerebrovascular disease and increased serum interleukin-6 levels in stroke patients, no difference in

### Table 5. Thrombophilia and Cryptogenic Stroke.

| Study | Ref | Results | Conclusions |
|-------|-----|---------|-------------|
| Gavva et al 143 patients with a stroke or TIA 2018 | 102 | 44 patients (31%) had at least 1 positive result. Most commonly elevated hereditary factor was protein S (11%) | Thrombophilia testing rarely impacted management and was costly |
| Alakbarzade et al 628 pts with stroke and TIA retrospective review 2018 | 101 | 360 patients tested 13/360—4% Factor V Leiden or prothrombin 20210A, 10/360 (2.8%) AT, PC or PS deficiency C, S or antithrombin was found rarely and was very uncommon in patients with TIA. There was weak follow-up | Very low incidence of antithrombin protein C and protein S. If one decides to test it should be repeated to distinguish bona fide thrombophilia from false positives |
| Ji et al 215 patients with ischemic stroke or TIA between the age of 18 and 45 Mean age 37.5 years 2012 | 100 | Factor V Leiden mutation 4/189 Prothrombin 20210A mutation 1///189 Protein C < 70% 2/189 Protein S < 70% 23/189 AT < 80 3/189 | Possibly numerous false positives—cutoffs for PC< 70%, PS <70% and AT < 80. Most common abnormal test—PS which is subject to acute phase effects |
| Botto et al 97 subjects with ischemic stroke or TIA compared with 160 age-matched controls, 55 yrs or younger | 99 | Combination of either Factor V Leiden or prothrombin 20210A mutation and patent foramen ovale was associated with a 4.7 fold increase in ischemic stroke or TIA in young patients (95% CI = 1.4 to 16.1; P = 0008). No statistically significant association was found with PC or PS or AT deficiencies | In cryptogenic stroke patients with PFO, 55 years or younger, prothrombotic factors such as FV Leiden and PT G20210A can help identify those with increased risk for ischemic stroke and adjust prevention treatment as needed |
demographics, vascular comorbidities, or -19 laboratory values were present in Covid stroke patients compared to known stroke patients. This finding however does not lead to a good explanation regarding the patient’s to be described below with isolated large vessel stroke.

COVID-19 stroke patients who require reperfusion or mechanical thrombectomy may pose complicated management problems because of concerns regarding neuroimaging and safety to healthcare workers performing this procedure. In fact, the number of these recanalization procedures has dropped considerably since the beginning of the pandemic.

With respect to young patients and the possible role of antiphospholipid antibodies in COVID-19 related strokes, a recent anecdotal report looked at 3 COVID-19 patients in China with strokes and found them to have antiphospholipid antibodies (APLAs). These patients had anticardiolipin IgA antibodies as well as anti-β2-glycoprotein I IgA and IgG antibodies. None were positive for lupus anticoagulant testing. The small number of patients, and the fact that they were predominantly IgA, generated skepticism as to their relevance, particularly since transient positivity for APLAs is common in acute infection. There are, however, data to suggest that IgA positivity but not IgM is correlated with thrombosis in lupus patients with APLA syndrome.

A recent collection of 5 COVID cases showed that large vessel stroke was a presenting sign in New York during the initial surge of COVID-19 hospitalizations in March and early April 2020. These were all individuals under age 50, who were previously healthy. None required mechanical ventilation. The report did not offer enough information to determine what the precise cause was for the possible Covid-19 related strokes. None of them had echocardiograms reported except the first of the 5 cases. Furthermore, none of them had tests reported for APLA; it is unknown whether patients could have had paradoxical emboli, arrhythmia, valvular lesions or APLAs, the most common causes of stroke in people under 50. D-dimer levels were significantly elevated in 3 of the 5 cases but there was no evidence of DIC. Furthermore among Stroke centers across the country, this spike of large-vessel occlusions in young people did not occur in the vast majority of centers.

In those people who have evidence of cytokine and thrombotic storm, strokes are probably part and parcel of the entire ongoing thrombotic process. However, there is a certain population of patients who sustain isolated large vessel thrombosis who may have other underlying pathologies that may be exacerbated by the acute viral infection, COVID-19.

Conclusions
Cerebral vein thrombosis can be treated with direct oral anticoagulants after initial heparin therapy and may possibly be used as a standalone drug in the future; however, that point needs to be clarified with further trials. Antiplatelet therapy or anticoagulation can be used to prevent stroke in cervical and vertebral dissection. There is no significant efficacy or safety difference between the 2. Anticoagulation with warfarin is preferred over DOACs for antiphospholipid syndrome; however concerns regarding negative data with DOAC use were mainly reported in arterial and triple positive patients. Eculuzumab is a promising agent for catastrophic antiphospholipid antibody syndrome.

Most cryptogenic ischemic stroke patients, age 60 or younger, with a patent foramen ovale, will benefit from closure, particularly those with large shunt size with and without septal aneurysm.

It is still unclear whether hereditary thrombophilia in patients without a patent foramen ovale predisposes to arterial stroke, however if it does, it is rare in adults. The data on COVID-19 associated strokes is still evolving. There is accumulating information regarding increased megakaryocytes deposition in multiple organs as NETS formation, as well as abnormal platelet function and cytokines driving these atypical strokes in young people.

Authors’ Note
Both Dr Song and Dr Berkman wrote the manuscript equally.

Declaration of Conflicting Interests
The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Dr Berkman is a speaker for Janssen Pharmaceuticals and Alexion. Dr Song is a principal investigator for the NIH StrokeNet site at Cedars-Sinai, a GORE REDUCE co investigator and has received honoraria for IMPACT-LIVE CME lectures.

Funding
The author(s) received no financial support for the research, authorship, and/or publication of this article.

ORCID iD
Samuel A. Berkman https://orcid.org/0000-0002-5610-0823

References
1. Ferro JM, Canhão or P, Stam J, Bousser MG, Barinagarrementeria F. Prognosis of cerebral vein and dural sinus thrombosis: results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT). Stroke. 2004;35(3):664-670.
2. Cumurciuc R, Crassard I, Sarov M, Valade D, Bousser MG. Headache as the only neurological sign of cerebral venous thrombosis: a series of 17 cases. J Neurol Neurosurg Psychiatry. 2005;76(8):1084-1087.
3. Stam J. Thrombosis of the cerebral veins and sinuses. N Engl J Med. 2005;352(17):1791-1798.
4. Bousser MG, Russell RR, Warlow CP, Van Gijn J, Saunders WB. Cerebral venous thrombosis. Maj Prob Neurol 1997;27:104.
5. Einhäupl K, Stam J, Bousser MG, et al. Guideline on the treatment of cerebral venous and sinus thrombosis in adult patients. Eur J Neurol. 2010;17(10):1229-1235.
6. Einhäupl KM, Villringer A, Meister W, et al. Heparin treatment in sinus venous thrombosis. Lancet. 1991;338(8767):597-600.
7. De Bruijn SF, Stam J. Randomized, placebo-controlled trial of anticoagulant treatment with low-molecular-weight heparin for cerebral sinus thrombosis. Stroke. 1999;30(3):484-488.
8. Stam J, De Bruijn SF, DeVeber G. Anticoagulation for cerebral sinus thrombosis. Cochrane Database Syst Rev. 2002;(4):CD002005.

9. Lansberg MG, O’Donnell MJ, Khatri P, et al. American college of chest physicians. Chest. 2012;141:e601S.

10. Furie KL, Kasner SE, Adams RJ, et al. American Heart Association Stroke Council, Council on Cardiovascular Nursing, Council on Clinical Cardiology, and Interdisciplinary Council on Quality of Care and Outcomes Research. Stroke. 2011;42(1):227-276.

11. Misra UK, Kalita J, Chandra S, Kumar B, Bansal V. Low molecular weight heparin versus unfractionated heparin in cerebral venous sinus thrombosis: a randomized controlled trial. Eur J Neurol. 2012;19(7):1030-1036. Epub 2012 Mar 15.

12. Coutinho JM, Ferro JM, Canhão P, Baringarrementeria F, Bousser MG, Stam J ISCVT Investigators. Unfractionated or low molecular weight heparin for the treatment of cerebral venous thrombosis. Stroke. 2010;41(11):2575-2580.

13. Ferro JM, Bousser MG, Canhão P, et al. European stroke organization guideline for the diagnosis and treatment of cerebral venous thrombosis—endorsed by the European Academy of Neurology. Eur J Neurol. 2017;24(10):1203-1213. doi:10.1111/ene.13381

14. EINSTEIN Investigators, Bauersachs R, Berkowitz SD, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363(26):2499-2510. doi:10.1056/NEJMoa1007903. Epub 2010 Dec 3. PMID: 21128814

15. Cohen AT, Hamilton M, Mitchell SA, et al. Comparison of the novel oral anticoagulants apixaban, dabigatran, edoxaban, and rivaroxaban in the initial and long-term treatment and prevention of venous thromboembolism: systematic review and network meta-analysis. PLoS One. 2015;10(12):e0144856. doi:10.1371/journal.pone.0144856. PMID: 26716830; PMCID: PMC4696796

16. Ferro JM, Coutinho JM, Dentali F, et al. Safety and efficacy of Dabigatran etexilate vs Dose-adjusted warfarin in patients with cerebral venous thrombosis, a randomized clinical trial. JAMA Neurol. 2019;76(12):1457-1465

17. Wasay M, Khan M, Rajput HM, et al. New oral anticoagulants versus Warfarin for cerebral venous thrombosis: a multi-center, observational study. J Stroke. 2019;21(2):220-223. doi:10.5853/jos.2019.00150

18. Lee GKH, Chen VH, Tan CH, et al. Comparing the efficacy and safety of direct oral anticoagulants with vitamin K antagonist in cerebral venous thrombosis [published online ahead of print, 2020 Apr 11]. J Thromb Thrombolysis. 2020;50(3):724-731. doi:10.1007/s11239-020-02106-7

19. Shankar Iyer R, Ter R, Akhtar S, Muthukalath K, Kumar P, Muthukumar K. Is it safe to treat cerebral venous thrombosis with oral rivaroxaban without heparin? A preliminary study from 20 patients. Clin Neurol Neurosurg. 2018;175:108-111. doi:10.1016/j.clineuro.2018.10.015

20. Herweth C, Griebe M, Geisbusch C, et al. Frequency and temporal profile of recanalization after cerebral vein and sinus thrombosis. Eur J Neurol. 2016;23(4):681-687.

21. Mendonca M, Barbosa R, Cruz-e-Silva V, Calado S, Viana-Baptista M. Oral direct thrombin inhibitor as an alternative in the management of cerebral venous thrombosis: a series of 15 patients. Int J Stroke. 2015;10(7):1115-1118. doi:10.1111/ijst.12462

22. Secret. www.clinicaltrials.gov space registration NCT03178864. Updated August 10, 2020.

23. Abbattista M, Cepecchi M, Martinelli I. Treatment of unusual thrombotic manifestations. Blood. 2020;135(5):326-334. doi:10.1182/blood.2019000918. PMID: 31917405

24. Leys D, Bandu L, Hénon H, et al. Clinical outcome in 287 consecutive young adults (15 to 45 years) with ischemic stroke. Neurology. 2002;59(1):26-33. doi:10.1212/wnl.59.1.26

25. Lee VH, Brown RD Jr, Mandrekar JN, Mokri B. Incidence and outcome of cerebral artery dissection: a population-based study. Neurology. 2006;67(10):1809-1812. doi:10.1212/01.wnl.0000244486.30455.71

26. Ning M, Gonzalez RG. Case 34-2013—a 69-year-old man with dizziness and vomiting. N Engl J Med. 2013;369(18):1736-1748.

27. Chaves C, Estol C, Esnaola MM, et al. Spontaneous intracranial internal carotid artery dissection: report of 10 patients. Arch Neurol. 2002;59(6):977-981.

28. Biller J, Sacco RL, Albuquerque FC, et al. Cervical arterial dissections and association with cervical manipulative therapy. A statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014;45(10):3155-3174.

29. Baldino G, Di Girolamo C, De Blasis G, Gori A. Eagle syndrome and internal carotid artery dissection: Description of five cases treated in two Italian institutions and review of the literature. Ann Vasc Surg. 2020;67:565.e17-565.e24. doi:10.1016/j.avsg.2020.02.033. Epub 2020 Mar 20. PMID: 32205242.

30. Brandt T, Haussner I, Orberk E, et al. Ultrastructural connective tissue abnormalities in patients with spontaneous cervicocerebral artery dissections. Ann Neurol. 1998;44(2):281-285. doi:10.1002/ana.40404224. PMID: 9708556.

31. Debette S, Grondf-Ginsbach C, Bodenant M, et al. Differential features of carotid and vertebral artery dissections The CADISS Study. Neurology. 2011;77(12):1174-1181. doi:10.1212/2wnl.0b013e31822f03fc

32. Menon R, Kenny S, Norris JW, Markus HS. Treatment of cervical artery dissection: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2008;79(10):1122-1127. doi:10.1136/jnnp.2007.138800

33. Kennedy F, Lanfranconi S, Hicks C. CADISS Investigators, et al. Antiplatelets vs anticoagulation for dissection: CADISS randomized arm and meta-analysis. Neurology. 2012;79(7):686-689. Epub 2012 Aug 1

34. Chowdhury MM, Sabbagh CN, Jackson D, Coughlin PA, Ghosh J. Antithrombotic treatment for acute extracranial carotid artery dissections: a meta-analysis. Eur J Vasc Endovasc Surg. 2015;50(2):148-156. doi:10.1016/j.ejvs.2015.04.034. Epub 2015 Jun 21. PMID: 26109428

35. CADISS trial investigators, Markus HS, Hayter E, et al. Antiplatelet treatment compared with anticoagulation treatment for cervical artery dissection (CADISS): a randomised trial [published correction appears in Lancet Neurol. 2015 Jun;14(6):566]. Lancet Neurol. 2015;14(4):361-367. doi:10.1016/S1474-4225(15)0018-9
36. Daou B, Hammer C, Mouchtouri S, et al. Anticoagulation vs antiplatelet treatment in patients with carotid and vertebral artery dissection: a study of 370 patients and literature review. *Neurosurgery*. 2017;80(3):368-379. doi:10.1093/neuros/nyw086
37. Georgiadis D, Arnold M, von Buedingen HC, et al. Aspirin vs anticoagulation in carotid artery dissection: a study of 298 patients. *Neurology*. 2009;72(21):1810-1815. doi:10.1212/WNL.0b013e3181a250a
38. Lansberg MG, O’Donnell MJ, Khatri P, et al. Antithrombotic and thrombolytic therapy for ischemic stroke: antithrombotic therapy and prevention of thrombosis. American College of Physicians. *Chest*. 2012;141(2 Suppl):e601S-e636S.
39. Kerman WN, Ovbiagele B, Black HR, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke*. 2014;45(7):2160-2236. doi:10.1161/STR.0000000000000024. Epub 2014 May 1. Erratum in: Stroke. 2015 Feb;46(2):e54. PMID: 24789897.
40. Cohen JE, Leker RR, Gottkin M, Gomori M, Ben-Hur T. Emergent stenting to treat patients with carotid artery dissection: clinically and radiologically directed therapeutic decision making. *Stroke*. 2003;34(12):e254-e257. doi:10.1161/01.STR.0000101915.11128.3D. Epub 2003 Nov 6. PMID: 14605318.
41. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). *J Thromb Haemost*. 2006;4(2):295-306. doi:10.1111/j.1538-7836.2006.01753.x
42. Akhter E, Shums Z, Norman GL, Binder W, Fang H, Petri M. Utility of antiphosphatidylserine/prothrombin and IgA antiphospholipid assays in systemic lupus erythematosus. *J Rheumatol*. 2013;40(3):282-286. doi:10.3899/jrheum.1200048.
43. Vargas-Hitos JA, Ateka-Barrutia O, Sangle S, Khamashta MA. Efficacy and safety of long-term low molecular weight heparin in patients with antiphospholipid syndrome. *Ann Rheum Dis*. 2011;70(9):1652-1654.
44. Lim W. Antiphospholipid antibody syndrome. *Hematology Am Soc Hematol Educ Program*. 2009;2009:233-239.
45. Panichpial K, Rozner E, Levine SR. The management of stroke in antiphospholipid syndrome. *Curr Rheumatol Rep*. 2012;14(1):99-106.
46. Crowther MA, Ginsberg JS, Julian J, et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. *N Engl J Med*. 2003;349(12):1133-1138.
47. Petri MA, Conklin J, O’Malley T, Dervieux T. Platelet-bound C4d, low C3 and lupus anticoagulant associate with thrombosis in SLE. *Lupus Sci Med*. 2019;6(1):e000318. Published March 30, 2019. doi:10.1136/lupus-2019-000318
48. Panichpial K, Rozner E, Levine SR. The management of stroke in antiphospholipid syndrome. *Curr Rheumatol Rep*. 2012;14(1):99-106.
49. Rodrigues CEM, Carvalho JF, Shoenfeld Y. Neurological manifestations of anti-phospholipid syndrome. *Eur J Clin Invest*. 2010;40(4):350-359.
50. Provenzale JM, Barboriak DP, Allen NB, Ortel TL. Patients with antiphospholipid antibodies: CT and MR findings of the brain. *AJR Am J Roentgenol*. 1996;167(6):1573-1578.
51. Babikian VL. Clinical and laboratory findings in patients with antiphospholipid antibodies and cerebral ischemia. The Antiphospholipid antibodies in stroke study group. *Stroke*. 1990;21(9):1268-1273.
52. Erdogan D, Goren MT, Diz-Kucukkaya R, Inanc M. Assessment of cardiac structure and left atrial appendage functions in primary antiphospholipid syndrome. *Stroke*. 2005;36(3):592-596.
53. Yelnik CM, Kozora E, Appenzeller S. Non-stroke central neurologic manifestations in antiphospholipid syndrome. *Curr Rheumatol Rep*. 2016;18(2):11.
54. Cervera R, Boffa M-C, Khamashta MA, Hughes GRV. The Euro-Phospholipid project: epidemiology of the antiphospholipid syndrome in Europe. *Lupus*. 2009;18(10):889-893.
55. De Carvalho JF, Pasoto SG, Appenzeller S. Seizures in primary antiphospholipid syndrome: the relevance of smoking to stroke. *Clin Dev Immunol*. 2012;2012:918519.
56. Cuadrado MJ, Khamashta MA, Ballesteros A, et al. Can neurologic manifestations of Hughes (antiphospholipid) syndrome be distinguished from multiple sclerosis? Analysis of 27 patients and review of the literature. *Medicine (Baltimore)*. 2000;79(1):57-68.
57. Cervera R, Pette JC, Font J, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. *Arthritis Rheum*. 2002;46(4):1019-1027.
58. Gris J, Cyprien F, Bouvier S, et al. Antiphospholipid antibodies are associated with positive screening for common mental disorders in women with previous pregnancy loss. The NOHA-PSY observational study. *World J Biol Psychiatry*. 2019;20(1):51-63. A cohort of 1,000 patients. *Arthritis Rheum* 2002;46(4):1019-1027. Epub 2017 Jun 19.
59. Sherer Y, Hassin S, Shoenfeld Y, et al. Transverse myelitis in patients with antiphospholipid antibodies—the importance of early diagnosis and treatment. *Clin Rheumatol*. 2002;21(3):207-210.
60. Appenzeller S, Yeh S, Maruyama M, Barros SM, De Carvalho JF. Chorea in primary antiphospholipid syndrome is associated with rheumatic fever. *Rheumatol Int*. 2012;32(9):2857-2861.
61. Ginsberg JS, Wells PS, Brill-Edwards P, et al. Antiphospholipid antibodies and venous thromboembolism. *Blood*. 1995;86(10):3685-3691.
62. Ruffatti A, Tonello M, Del Ross T, et al. Antibody profile and antibody intensity of anti-phospholipid antibodies in stroke study group. *Stroke*. 1990;21(9):1268-1273.
63. Bick RL, Rice J. Long-term outpatient dalteparin (fragmin) therapy for arterial and venous thrombosis: efficacy and safety—a preliminary report. *Clin Appl Thromb Hemost*. 1999;5(1):S67-S71.
64. Finazzi G, Marchioli R, Brancaccio V, et al. A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). *J Thromb Haemost*. 2005;3(5):848-853.
65. Bertsias G, Ioannidis JP, Boletis J, et al. EULAR recommendations for the management of systemic lupus erythematosus. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. *Ann Rheum Dis*. 2008;67(9):195-205.

66. Levine SR, Brey RL, Tilley BC, et al. APASS Investigators. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. *JAMA*. 2004;291(5):576-584.

67. Cohen H, Hunt BJ, Ethfhiymiou M, et al. Rivaroxaban versus warfarin to treat patients with thrombosis antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomized, controlled, open-label, phase 2/3, non-inferiority trial. *Lancet Haematol*. 2016;3(9):e426-e436. doi:10.1016/S2352-3026(16)30079-5

68. Prego V, Denas G, Zoppellaro G, et al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. *Blood*. 2018;132(13):1365-1371. doi:10.1182/blood.2018-04-848333

69. Ordi-Ros J, Sáez-Comet L, Pérez-Conesa M, et al. Rivaroxaban versus vitamin K antagonist in antiphospholipid syndrome: a randomized noninferiority trial. *Ann Intern Med*. 2019;171(10):685-694. doi:10.7326/M19-0291

70. Dufrost V, Risse J, Reshetnyak T, et al. Increased risk of thrombosis in antiphospholipid syndrome patients treated with direct oral anticoagulants. Results from an international patient-level data meta-analysis. *Autoimmun Rev*. 2018;17(10):1011-1021. doi:10.1016/j.autrev.2018.04.009

71. Cohen H. The use of direct oral anticoagulants and antiphospholipid syndrome. *Clin Adv Hematol Oncol*. 2020;18(1):19-22.

72. ISRCTN Registry. Rivaroxaban for stroke patients with antiphospholipid syndrome. doi:10.1186/ISRCTN10280992. Updated July 26, 2019. Accessed December 4, 2019.

73. International Society on Thrombosis and Haemostasis. International registry of thrombotic APS patients treated with direct oral anticoagulants. Accessed December 4, 2019. https://cdn.ymaws.com/www.isth.org/resource/resmgr/subcommittees/registry_on_doacs_in_aps_pro_PDF.pdf

74. European Medicines Agency. New product information wording: extracts from PRAC recommendations on signals. Updated April 2019. Accessed December 4, 2019. https://www.ema.europa.eu/en/documents/other/new-product-information-wording-extracts-prac-recommendations-signalsadopted-8-11-april-2019-prac_en.pdf

75. Konstantinides SV, Meyer G. The 2019 ESC guidelines on the diagnosis and management of acute pulmonary embolism. *Eur Heart J*. 2019;40(42):3453-3455. doi:10.1093/eurheartj/ehz726

76. Brodsky RA. Complement in hemolytic anemia. *Blood*. 2015;126(22):2459-2465. doi:10.1182/blood.2015-06-640995

77. Strakhán M, Hurtado-Sbordoni M, Galeas N, Bakirhan K, Alexis K, Elrefai T. 36-year-old female with catastrophic antiphospholipid syndrome treated with eculizumab: a case report and review of literature. *Case Rep Hematol*. 2014;2014:704371. doi:10.1155/2014/704371

78. Pezzini A, Del Zotto E, Magoni M, et al. Inherited thrombophilic disorders in young adults with ischemic stroke and patent foramen ovale. *Stroke*. 2003;34(1):28-33.

79. Bendixen B, Posner J, Lango R. Stroke in young adults and children. *Curr Neurol Neurosci Rep*. 2001;1(1):54-66.

80. Carroll C, Saver J, Thaler D, et al. Closure of patent foramen ovale versus medical therapy after cryptogenic stroke. *N Engl J Med*. 2013;368(12):1092-1100.

81. Meier B, Kalesan B, Mattle H, et al. Percutaneous closure of patent foramen ovale in cryptogenic embolism. *N Engl J Med*. 2013;368(12):1083-1091.

82. Furlan A, Reisman M, Massaro J, et al. Closure or medical therapy for cryptogenic stroke with patent foramen. *N Engl J Med*. 2012;366(11):991-999.

83. Messe S, Kent D. Still no closure on the question of PFO closure. *N Engl J Med*. 2013;368(12):1152-1153.

84. Saver JL, Carroll JD, Thaler DE, et al. Respect Investigators. Long-term outcomes of patent foramen ovale closure or medical therapy after stroke. *N Engl J Med*. 2017;377(14):1022-1032. doi:10.1056/NEJMoa1700507

85. Sondergaard L, Kasner SE, Rhodes JF, et al. Gore reduce clinical study investigators. Patent foramen ovale closure or antiplatelet therapy for cryptogenic stroke. *N Engl J Med*. 2017;377(11):1033-1042. doi:10.1056/NEJMoa1707404

86. Mas JL, Derumeaux G, Guillou B, et al. Close Investigators. Patent foramen ovale closure or antiagulation vs. antiplatelets after stroke. *N Engl J Med*. 2017;377(11):1011-1021. doi:10.1056/NEJMoa1705915

87. Lee PH, Song JK, Kim JS, et al. Cryptogenic stroke and high-risk patent foramen ovale: the defense-PFO trial [published online ahead of print February 28, 2018]. *J Am Coll Cardiol*. 2018;71(20):2335-2342. doi:10.1016/j.jacc.2018.02.046

88. Zadro R, Herak D. Inherited prothrombotic risk factors in children with first ischemic stroke. *Bio Med*. 2012;22(3):298-310.

89. Whitlock JA, Janco RL, Phillips JA 3rd. Inherited hypercoagulable states in children. *Am J Pediatrics Hematol Oncol*. 1989;11(2):170-173.

90. Kenet G, Lutkoff I, Albisetti M, et al. Impact of thrombophilia on risk of arterial ischemic stroke or cerebral sinovenous thrombosis in neoates and children: a systematic review and meta-analysis of observational studies. *Circulation*. 2010;121(16):1838-1847.

91. Kim RJ, Becker RC. Association between factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations and events of the arterial circulatory system: a meta-analysis of published studies. *Am Heart J*. 2003;146(6):948-957.

92. Ridker PM, Hennekens C, Miletich JP. G20210A mutation in prothrombin gene and risk of myocardial infarction, stroke, and venous thrombosis in a large cohort of US Men. *Circulation*. 1999;99(8):999-1004.

93. Cushman M, Rosendaal FR, Psaty BM, et al. Factor V Leiden is not a risk factor for arterial vascular disease in HRE elderly; results from the Cardiovascular Health Study. *Am Heart J*. 1999;137(5):912-915.

94. Israels SJ, Seshia SS. Childhood stroke associated with Protein C and S deficiency. *J Pediatr*. 1987;111(4):562-564.

95. Green D, Otoya J, Oriba H, Rovnre R. Protein S deficiency in middle aged women with stroke. *Neurology*. 1992;42(5):1029-1033.
96. Mayer S, Sacco R, Hurlet-Jensen A, Shi T, Mohr JP. Free protein S deficiency in acute ischemic stroke: a case control study. *Stroke*. 1993;24(2):224-227.

97. Fields MC, Levine SR. Thrombophilia and stroke: diagnosis, treatment and prognosis. *J Thromb Thrombolysis*. 2005;20(2):113-126.

98. Weih M, Junge-Hülsing J, Mehraein S, Ziemer S, Einhäupl KM. Hereditäre thrombophilien bei ischämischem schlaganfall und sinusvenenthrombose. Diagnostik, therapie und meta-analyse [Hereditary thrombophilia with ischemic stroke and sinus thrombosis. Diagnosis, therapy and meta-analysis]. *Nervenarzt*. 2000;71(12):969-974. doi:10.1007/s001150050690

99. Botto N, Spadoni I, Giusti S, Ait-Ali L, Sicari R, Andreassi MG. Prothrombotic mutations as risk factors for cryptogenic ischemic cerebrovascular events in young subjects with patent foramen ovale. *Stroke*. 2007;38(7):2070-2073. doi:10.1161/STROKEAHA.106.480863

100. Ji R, Schwamm LH, Pervez MA, Singhal AB. Ischemic stroke and transient ischemic attack in young adults: risk factors, diagnostic yield, neuroimaging, and thrombolysis. *JAMA Neurol*. 2013;70(1):51-57. doi:10.1001/jamaneurol.2013.575

101. Alakbarzade V, Taylor A, Scully M, Simister R, Chandratheva A. Utility of current thrombophilia screening in young patients with stroke and TIA. *Stroke Vasc Neurol*. 2018;3(4):231-236. Published September 12, 2018. doi:10.1136/svn-2018-000169

102. Gavva C, Johnson M, De Simone N, Sarode R. An audit of thrombophilia testing in patients with ischemic stroke or transient ischemic attack: the futility of testing. *J Stroke Cerebrovasc Dis*. 2018;27(11):3301-3305. doi:10.1016/j.jstrokecerebrovasdis.2018.07.032

103. Ellul MA, Benjamin L, Singh B, et al. Neurological associations of COVID-19. *Neurology*. 2020;95(1):176-184. doi:10.1212/WNL.0000000000009356

104. Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endotheliitis in COVID-19. *Lancet*. 2020;395(10164):1417-1418.

105. Wang Z, Yang Y, Liang X, et al. COVID-19 associated ischemic stroke and hemorrhagic stroke: incidence, potential pathological mechanism, and management. *Front Neurol*. 2020;11. doi: 10.3389/fneur.2020.571996. PMID: 33193019; PMCID:PMC7652923.

106. Merkler AE, Parikh NS, Mir S, et al. Risk of ischemic stroke in patients with coronavirus disease 2019 (COVID-19) vs patients with influenza [published online ahead of print, 2020 Jul 2]. *JAMA Neurol*. 2020;77(11):e202730. doi:10.1001/jamaneurol.2020.2730

107. Siepmann T, Sedghi A, Simon E, et al. Increased risk of acute stroke among patients with severe COVID-19: a multicenter study and meta-analysis. *Eur J Neurol*. 2021;28(1):238-247. doi:10.1111/ene.14535. Epub 2020 Oct 16. PMID: 32920964.

108. Qureshi AI, Abd-Allah F, Al-Senani F, et al. Management of acute ischemic stroke in patients with COVID-19 infection: report of an international panel [published correction appears in Int J Stroke. 2020 Jun 22;1747493020935996]. *Int J Stroke*. 2020;15(5):540-554. doi:10.1177/1747493020923234

109. Kansagra AP, Goyal MS, Hamilton S, Albers GW. Collateral effect of Covid-19 on stroke evaluation in the United States. *N Engl J Med*. 2020;383(4):400-401. doi:10.1056/NEJMc2014816

110. Zhang Y, Xiao M, Zhang S, et al. Coagulopathy and Antiphospholipid herantibodies in patients with Covid-19. *N Engl J Med*. 2020;382(17):e38. doi:10.1056/NEJMc2007575

111. Akhter E, et al. IgG and IGA Beta2-GPI are associated with venous thrombosis in SLE. *J Rheumatol*. 2013;40:2382-2386.

112. Dominguez V, Magder LS, Petri M. IgM anticardiolipin is not associated with lifetime rates of thrombotic events. *Lupus Sci Med Lupus Sci Med*. 2016;3(1):e000107. doi:10.1136/lupus-2015-000107

113. Oxley T, Mocco J, Majidt S, et al. Large vessel stroke as a presenting feature of Covid19 in the young. *N Engl J Med*. 2020;382(20):e60. doi: 10.1056/c2009787

114. Rapkiewicz AV, Mai X, Carsons SE, et al. Megakaryocytes and platelet-fibrin thrombi characterize multi-organ thrombosis at autopsy in COVID-19: a case series, *EClinicalMedicine*. 2020;24:100434. doi.org/10.1016/j.eclinm.2020.100434

115. Middleton EA, He XY, Denome F, et al. Neutrophil Extracellular Traps (NETs) Contribute to Immunothrombosis in COVID-19 Acute respiratory distress syndrome [published online ahead of print, 2020 Jun 29]. *Blood*. 2020;10-36(10): 1169-1179. doi:10.1182/blood.2020007008